Rupitasertib, our first-in-class double node PAM inhibitor EVX020, our first-in-class KIF20A inhibitor Latest news Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer August 4, 2026 Evexta Bio Appoints Edith A. Perez as Scientific Advisor October 25, 2024 Evexta Bio appoints Shawn M. Leland as Chairman of the Board of Directors June 19, 2024
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer August 4, 2026
